Aeterna Zentaris Inc. (NASDAQ:AEZS) Sees Large Growth in Short Interest

Aeterna Zentaris Inc. (NASDAQ:AEZSGet Free Report) (TSE:AEZ) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 23,200 shares, a growth of 10.0% from the January 31st total of 21,100 shares. Based on an average daily trading volume, of 14,600 shares, the short-interest ratio is presently 1.6 days. Currently, 0.5% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. StockNews.com initiated coverage on Aeterna Zentaris in a report on Tuesday. They set a “sell” rating on the stock. HC Wainwright lowered their price objective on shares of Aeterna Zentaris from $28.00 to $15.00 and set a “buy” rating for the company in a research report on Monday, November 13th.

Check Out Our Latest Research Report on Aeterna Zentaris

Aeterna Zentaris Price Performance

Shares of AEZS stock opened at $1.91 on Tuesday. Aeterna Zentaris has a 52 week low of $1.36 and a 52 week high of $3.41. The firm has a 50 day moving average of $1.89 and a two-hundred day moving average of $2.03.

Aeterna Zentaris Company Profile

(Get Free Report)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

Featured Articles

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.